IGC
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
India Globalization Capital carries a Neutral rating with three-out-of-five conviction, reflecting a composite score of 40 and an uneven pillar profile. Regulatory is the strongest contribution at 49, supported by an 80 enforcement subscore and a 50 jurisdiction assessment. Market stands at 40 despite the absence of an available quote, while fundamentals trail at 38 as gross-margin strength is overwhelmed by operating losses and limited scale. Editorial ranks lowest at 30, consistent with no newsroom or brief activity in CIN newsroom coverage. The resulting band appropriately balances a comparatively stable regulatory profile against stretched financial condition, weak profitability, sparse filing visibility, and minimal coverage momentum.
Licensed fundamentals data show year-over-year revenue contracting by approximately 3.9%, leaving the revenue-growth subscore near 46. Gross margin remains the clearest operating positive at roughly 46.2%, producing a strong 77 subscore, but the operating margin is deeply negative at about 723% below breakeven and receives no subscore contribution. EBITDA is negative by approximately $7.5 million, while reported net income is zero; neither figure offsets the stretched classification. A market capitalization near $28.4 million contributes a low scale subscore of roughly 18, and the cash-burn ratio of approximately 26.5% supports only a 41-level runway assessment. Primary regulatory filings show no recorded filing date and no events across either the prior 90-day or 180-day periods, producing a cadence subscore of 25. Institutional pricing feeds also provide no available quote, constraining market-pillar confirmation.
The clearest forward catalyst sits within the regulatory pillar, where the absence of enforcement hits already supplies the company’s strongest individual driver. That strength remains incomplete because filing cadence materially lags the enforcement contribution. A timely primary regulatory filing with substantive operating and financial detail would lift transparency, refresh the stale cadence signal, and enable clearer assessment of revenue direction, margin durability, and the stretched financial position. Such an event would carry greater rating relevance than an isolated coverage item because regulatory already leads the pillar set and has the widest identifiable route to incremental improvement. The single most important signal to watch is the arrival of a fresh primary regulatory filing that restores cadence and updates the financial record.
- IR / PR agency
- IMS Investor Relations
- IR email
- [info@igcpharma.com](mailto:info@igcpharma.com)
- IR page
- Investor relations
- Headquarters
- 10224 FALLS ROAD, POTOMAC, MD, 20854
- Phone
- 301-529-4996
- CEO
- Ram Mukunda
- CFO
- Claudia Grimaldi
- SEC CIK
- 1326205
- Website
- Company website
- Market cap
- $28.4M
- Enterprise value
- $29.1M
- Price to book
- 4.64
- Price to sales
- 25.67
- EV / EBITDA
- 27.31
- Revenue (TTM)
- $1.1M
- Gross profit (TTM)
- $511K
- EBITDA
- $-7.5M
- Operating margin
- -722.7%
- Profit margin
- 0.0%
- Rev growth YoY
- -3.9%
- Return on equity
- -83.3%
- Return on assets
- -50.3%
- EPS (TTM)
- $-0.06
- EPS est. current year
- $-0.08
- Wall St. target price
- $4.25
- Shares outstanding
- 104.4M
- Insider ownership
- 13.4%
- Institutional ownership
- 21.7%
- Beta
- 0.46
- Full-time employees
- 70
- GICS sector
- Healthcare
- GICS industry
- Biotechnology
- Annual report
- Latest 10-K
- Proxy statement
- Latest DEF 14A
- Filing portal
- SEC EDGAR
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for IGC (IGC)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for IGC (IGC), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for IGC are maintained by Cannabis Investor News and refreshed throughout the trading day.